Compositions and methods for the prevention and treatment of cardiovascular diseases
Inventors
Van Wyk, Henk • Van Wyk, Mariette • Krebs, Trace • Lange, Peter • Denomme, Brian • Volk, Michael A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11110053-B2
Publication Date
2021-09-07
Expiration Date
Abstract
Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
Core Innovation
The invention relates to a therapeutic composition comprising an electro-activated solution having a stable negative oxidation-reduction potential in a defined range, together with specified conductivity and pH. The electro-activated solution is formed from multiple salts and vitamins and electrochemically activated water. The composition includes defined percentages for magnesium sulfate hexahydrate, ascorbic acid, niacinamide, pyridoxin HCl, calcium D pantothenate, thiamin HCl, riboflavin, cyanocobalamin, sodium bicarbonate, and sodium chloride, constrained by the negative oxidation-reduction potential, conductivity, and pH.
A further inventive concept is the preparation of the therapeutic composition by mixing two electroactivated solutions: a first electroactivated solution having a stable negative oxidation-reduction potential and an acidic pH, and a second electroactivated solution having a stable positive oxidation-reduction potential and a near-neutral pH. The mixing step uses equal volumes of the first and second electroactivated solutions. The resulting composition is defined by stable negative oxidation-reduction potential, conductivity, and pH constraints.
The document also emphasizes stability of the electroactivated solutions over extended periods and provides mechanistic rationale for cardiovascular related prevention or treatment. It describes that the electro-activated solution is associated with membrane permeability and trans-membrane potential, and also relates the solution to oxidative stress concepts such as ROS and LDL oxidation/foam cell and atherosclerosis.
Claims Coverage
The partial content provided includes two independent claims. Each independent claim focuses on parameter-defined electro-activated solutions characterized by stable oxidation-reduction potential, conductivity, and pH, with one claim specifying a single directly defined composition and the other claim specifying composition formed by mixing two differently characterized electroactivated solutions, including stability ranges for each component solution.
Electro-activated therapeutic composition with stable negative oxidation-reduction potential
A therapeutic composition consisting of an electro-activated solution with a stable negative oxidation-reduction potential in a range between 50 mV and 500 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the electro-activated solution consisting of specified ranges of magnesium sulfate hexahydrate, ascorbic acid, niacinamide, pyridoxin HCl, calcium D pantothenate, thiamin HCl, riboflavin, cyanocobalamin, sodium bicarbonate, sodium chloride, and electrochemically activated water.
Therapeutic composition formed by mixing stable negative and stable positive electroactivated solutions
A therapeutic composition consisting of the product of mixing a first electroactivated solution having a stable negative oxidation-reduction potential and acidic pH with a second electroactivated solution having a stable positive oxidation-reduction potential and near-neutral pH, wherein the first electroactivated solution and the second electroactivated solution are each defined by stability ranges for oxidation-reduction potential and pH, and the mixing comprises equal volumes of the first electroactivated solution and the second electroactivated solution.
Across the two independent claims, the core claimed coverage is compositions defined by stable negative oxidation-reduction potential with specified conductivity and pH. One claim directly defines the electro-activated formulation as a single mixture of specified salt/vitamin ranges with electrochemically activated water, while the other claim defines the therapeutic composition as the product of mixing equal volumes of two electroactivated solutions—one acidic stable negative redox solution and one near-neutral stable positive redox solution—with specified stability ranges and compositional constraints for each solution.
Stated Advantages
The document emphasizes stability of the electroactivated solutions over extended periods.
It provides mechanistic rationale for cardiovascular related prevention or treatment.
Reported example outcomes include changes in calcium plaque scores and symptomatic improvements in angina and Buerger’s disease, with no reported side effects.
Documented Applications
Cardiovascular related prevention or treatment.
Changes in calcium plaque scores.
Symptomatic improvements in angina and Buerger’s disease.
Interested in licensing this patent?